The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a ...

Statement/Regulatory AdmissionFormycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama® 18.11.2024 / 06:30 ...

Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic colorectal cancer: Princeton, New Jersey Monday, November 18, 2 ...

EMA encourages companies to submit type I variations for 2024 by end November 2024: Amsterdam, The Netherlands Monday, November 18, 2024, 14:00 Hrs [IST] European Medicines Agency ...

Despite their promise, these therapies have faced significant regulatory and access challenges. In July, the European ...

Healthcare products provider RHEA Generics is committed to promoting affordable healthcare by offering generic medications ...

The European Union's pharmaceutical reforms must maintain the current patent protection baseline, says David Kolář, executive ...

Robert F. Kennedy Jr. has pledged to tackle high rates of chronic diseases such as diabetes and obesity as President-elect ...

These bacteria have evolved the ability to resist treatment with antibiotics, and it's making them more deadly and harder to ...

Detailed price information for Pliant Therapeutics Inc (PLRX-Q) from The Globe and Mail including charting and trades.

ORLADEYO ® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary ...

Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines ...